SciBits

‘Me and My Drank’: Exploring the Relationship Between Musical Preferences and Purple Drank Experimentation

1. Survey-based study exploring links between musical preference and purple drank use.
2. Hip-hop and rap fans reported significantly higher experimentation with lean.
3. Cultural symbolism of purple drank strongly embedded in lyrics and imagery.
4. Highlights normalization of opioid cough syrup misuse among youth.
5. Suggests that musical subculture serves as both a risk factor and prevention target.

Purple drank: un dangereux cocktail à connaître

1. Clinical report describing cases of adolescents hospitalized due to purple drank intoxication.
2. Identifies codeine-promethazine syrup combined with soda as primary preparation.
3. Notes complications including respiratory depression and neurological effects.
4. Warns of increasing popularity among French youth influenced by US culture.
5. Calls for physician awareness and preventive education targeting adolescents.

Purple Drank, Sizurp, and Lean: Hip-Hop Music and Codeine Use

1. Examines portrayal of lean in hip-hop music videos and lyrics.
2. Identifies strong influence of artists in glamorizing codeine-promethazine use.
3. Discusses normalization of risky drinking behaviors in youth culture.
4. Argues that hip-hop serves as a driver of lean’s global diffusion.
5. Calls for public health educators to address cultural representations directly.

Beyond the ‘purple drank’: Study of promethazine abuse according to EMA adverse drug reaction reports

1. EMA pharmacovigilance data analyzed for promethazine abuse and misuse cases.
2. 36% of ADR reports linked to misuse, abuse or dependence.
3. Fatal cases often involved co-ingestion with opioids or benzodiazepines.
4. Promethazine misuse reported across Europe and US youth populations.
5. Authors emphasize the need for stricter monitoring and awareness among clinicians.

Adolescent Substance Use and Misuse: Recognition and Management

1. Reviews prevalence and patterns of adolescent substance use, including lean.
2. Notes disparities in lean misuse among Black, Hispanic and Native American youth.
3. Recommends validated screening tools for primary care clinicians.
4. Highlights motivational interviewing and SBIRT as effective interventions.
5. Stresses importance of confidentiality and integrated care approaches.

Lean/Sizzurp Ingredients, Use, and Coping With Mental Health Symptoms

1. Cross-sectional survey of 1,423 Reddit-recruited adults with past-year lean use examined ingredients, use patterns, and coping-related use.
2. Reported ingredients included codeine (74.5%), promethazine (31.7%), and both combined (13.5%).
3. Anxiety, lifetime trauma exposure, and female sex were associated with higher odds of using lean to cope with emotions in the past 30 days.
4. Depression and unstable housing were associated with lower odds of coping-motivated lean use in the past 30 days.
5. The study introduced lean-specific screening tools (LUDIT; Lean Use Disorder items) and highlighted overdose/toxicity risks and the need for population-level research.

Management of opiate dependence related to dihydrocodeine–sorbitol misuse

1. Two Australian cases of dependence on over‑the‑counter dihydrocodeine–sorbitol cough mixture (“Rikodeine”) are described in the context of recreational 'lean' use.
2. In Australia, 'lean' typically involves dihydrocodeine (given the unavailability of codeine–promethazine), sometimes mixed with soft drink and promethazine.
3. Dihydrocodeine is not detected on standard urine drug screens and is often overlooked clinically, which can delay appropriate treatment.
4. Both patients were successfully transitioned to opioid agonist therapy, underscoring treatment pathways for this understudied opioid misuse.
5. The article highlights increased awareness needs since codeine rescheduling (2018) and the importance of harm‑reduction counseling.

Use of “Lean” Among Electronic Dance Music Party Attendees

1. Time–space sampled survey of 1,029 NYC EDM party attendees estimated 15.5% lifetime, 3.4% past‑year, and 0.2% past‑month lean use.
2. Willingness to use if offered in the next 30 days was 14.2%, markedly higher among those with prior use.
3. Three‑quarters of users believed their lean ever contained codeine, and 32.4% believed it always/usually did.
4. Past‑year lean use was strongly associated with past‑year nonmedical prescription opioid use (aOR ≈ 10.8) but not with most other drugs.
5. Higher odds of past‑year use were observed among Black and bisexual attendees, while a college degree was protective.

Representations of Codeine Misuse on Instagram: Content Analysis

1. Content analysis of 1,156 Instagram posts identified common lean imagery (purple drink, double cups) and preparation rituals.
2. Codeine misuse was frequently depicted with alcohol, cannabis, and benzodiazepines, reflecting polysubstance use risks.
3. Posts often invoked hip‑hop/trap aesthetics and brand references, reinforcing subcultural identity.
4. The ubiquity and aesthetics of posts suggest normalization, ritualization, and commercialization of codeine misuse.
5. Authors call for harm‑reduction messaging to counter glamorization and teach safer practices to at‑risk youth.

Evidence-Based Pharmacotherapies for Alcohol Use Disorder: Clinical Pearls

1. Large RCT comparing naltrexone, acamprosate, both, or placebo for AUD.
2. Naltrexone significantly reduced heavy drinking days; acamprosate showed no superiority to placebo.
3. Combined treatment offered no clear advantage over naltrexone alone.
4. All groups improved with behavioral intervention, highlighting importance of psychosocial support.
5. Adherence was a major predictor of outcomes.

Alcohol use disorder: Pharmacologic management

1. Reviews FDA/EMA-approved medications: naltrexone, acamprosate, disulfiram, and nalmefene (EU).
2. Discusses off-label and emerging agents (gabapentin, topiramate, baclofen, ondansetron, varenicline, aripiprazole).
3. Emphasizes tailoring treatment to patient profile (goal: abstinence vs. reduction).
4. Highlights need for concurrent psychosocial interventions.
5. Notes barriers: underprescribing, adherence challenges, side effects, stigma.

A Narrative Review of Current and Emerging Trends in the Treatment of Alcohol Use Disorder

1. Reviews approved, repurposed, and novel agents for AUD.
2. Approved: disulfiram, acamprosate, naltrexone, nalmefene; regionally approved: baclofen, sodium oxybate.
3. Repurposed: topiramate, gabapentin, varenicline, aripiprazole, ondansetron.
4. Novel: mifepristone, ibudilast, suvorexant, prazosin, doxazosin, N-acetylcysteine, GET73, ASP8062, ABT-436, PF-5190457, cannabidiol.
5. Emphasizes heterogeneity of AUD and precision medicine approaches.

Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder

1. Scoping review of integrating AUD pharmacotherapy into U.S. primary care.
2. Identified 47 studies, 25 primary (44% RCTs).
3. Medications: mainly naltrexone, acamprosate, disulfiram.
4. Integrated models varied (co-location, direct prescribing, collaborative care).
5. Outcomes: significant improvements in initiation, engagement, and reduced alcohol consumption.

Combination of Drugs in the Treatment of Alcohol Use Disorder: A Meta-Analysis and Meta-Regression Study

1. Review of baclofen in AUD treatment.
2. Evidence shows reduction of craving and heavy drinking in some subgroups.
3. Effectiveness remains controversial due to heterogeneity of RCT outcomes.
4. Baclofen considered useful in patients with anxiety, liver disease, or treatment resistance.
5. Calls for precision medicine approaches and more stratified trials.

Efficacy of medications for the treatment of alcohol use disorder (AUD): A systematic review and meta-analysis considering baseline AUD severity

1. Reviews precision medicine in AUD pharmacotherapy.
2. Emphasizes heterogeneity of treatment response to approved and off-label medications.
3. Highlights genetic, neurobiological, and clinical moderators of medication effects.
4. Supports use of biomarkers and patient profiling to guide medication choice.
5. Suggests future trials must incorporate personalized approaches to improve efficacy.

Pharmacotherapy for Adults With Alcohol Use Disorder in Outpatient Settings: Systematic Review

1. Reviews role of GABAergic medications in AUD (e.g., baclofen, sodium oxybate).
2. Summarizes efficacy in withdrawal, craving reduction, and relapse prevention.
3. Notes benefits in patients with liver disease or psychiatric comorbidities.
4. Discusses risks: sedation, dependence, and overdose potential.
5. Recommends cautious, individualized prescribing and more RCTs.

Integration of Pharmacotherapy for Alcohol Use Disorder Treatment in Primary Care Settings: A Scoping Review

1. Systematic review/meta-analysis of perioperative alcohol interventions.
2. Screening and short-term abstinence programs reduce postoperative complications.
3. Pharmacological support (acamprosate, disulfiram) beneficial but underused.
4. Demonstrates cost-effectiveness of pre-surgical alcohol interventions.
5. Highlights need for routine integration into surgical pathways.

Synthetic Cathinones and Neurotoxicity Risks: A Systematic Review

1. Systematic review of human and animal evidence links synthetic cathinones to CNS toxicity, including encephalopathy, seizures, and coma.
2. Describes characteristic toxidromes—sympathomimetic and hallucinogenic—plus risks of excited/agitated delirium and serotonin syndrome.
3. Summarizes intoxication and fatality cases, highlighting dose/formulation variability and polydrug contributions.
4. Compiles preclinical findings (rats, mice, zebrafish) showing neurochemical dysregulation and brain injury markers.
5. Calls for strengthened monitoring, standardized reporting, and targeted harm-reduction for cathinone exposures.

Synthetic Cathinones: Epidemiology, Toxicity, Potential for Abuse, and Current Public Health Perspective

1. Reviews epidemiology and market trends of synthetic cathinones, outlining common subclasses and prevalent analogs (e.g., mephedrone, MDPV, methylone).
2. Summarizes acute and chronic toxicity profiles with emphasis on neurotoxicity and adverse psychiatric/medical effects.
3. Highlights abuse potential and reinforcing properties relative to other psychostimulants, including risks from polydrug combinations.
4. Discusses current public health responses: harm-reduction, education, and clinical management strategies.
5. Identifies surveillance gaps and recommends integrated monitoring to mitigate population-level harms.

A review of synthetic cathinones emerging in recent years (2019–2022)

1. Identifies 29 newly detected cathinones (2019–mid-2022) with structural descriptions and first detection by country and date.
2. Collates clinical features from case reports, including non-fatal and fatal poisonings with measured concentrations.
3. Compares pharmacological profiles of known cathinones to infer risks for newer analogs lacking direct studies.
4. Emphasizes analytical challenges and the role of early-warning systems and user forums in detection.
5. Concludes many new entries are replacements for controlled drugs and may escalate in prevalence over time.

Flakka: New Dangerous Synthetic Cathinone on the Drug Scene

1. Comprehensive review of α‑pyrrolidinopentiophenone (α‑PVP, “Flakka”): history, synthesis, SAR, metabolism, pharmacology, and toxicology.
2. Describes DAT/NET reuptake inhibition underlying potent psychostimulant effects and high abuse liability.
3. Details clinical presentations including agitated delirium, severe sympathetic activation, hyperthermia, and seizures, with multiple fatalities.
4. Summarizes forensic detection, case series, and international regulatory control measures.
5. Recommends improved analytical methods and public health interventions to address rising harms.

Fentanyl and other New Psychoactive Synthetic Opioids. Challenges to Prevention and Treatment

1. Review of fentanyl and novel synthetic opioids (including nitazenes and U-series), their chemistry, potency, and pharmacology.
2. Describes the increase in illicit production and distribution and the resulting overdoses.
3. Highlights detection and regulatory challenges, noting the need for broad-spectrum analytical methods.
4. Clinical management includes naloxone and opioid agonist therapies, with emphasis on structured protocols.
5. Prevention requires surveillance, education, and coordinated public health measures.

Nitazenes: review of comparative pharmacology and antagonist action

1. Nitazene derivatives are highly potent µ-opioid receptor agonists with strong intrinsic efficacy.
2. They produce marked respiratory depression and sometimes life-threatening chest wall rigidity.
3. Different analogs show heterogeneous pharmacological profiles, including activity at δ/κ receptors.
4. Antagonism with µ-opioid antagonists such as naloxone is possible, but the effectiveness varies between analogs.
5. Clinically, early and adequately dosed antagonism should be considered, and toxicological surveillance for new nitazenes must be reinforced.

Nitazenes: Old Drugs and New Challenges: A Narrative Review

1. Narrative review of the emergence, pharmacology, and risks of nitazenes in the current illicit drug market.
2. Emphasizes their extreme potency and the considerable overdose risk associated with these compounds.
3. Describes challenges in toxicological detection and regulatory responses.
4. Discusses acute management including naloxone antagonism and typical clinical presentation (mainly respiratory depression).
5. Calls for coordinated public health responses with early warning systems, education, and harm reduction measures.

The anomalous pharmacology of fentanyl

1. Examines why fentanyl behaves differently pharmacologically compared with classical µ-opioid agonists (e.g., morphine, oxycodone).
2. High lipophilicity and rapid CNS penetration contribute to fast onset of action and pronounced respiratory depression.
3. Explores receptor kinetics and signaling as explanations for chest wall rigidity and enhanced efficacy.
4. Discusses how these unique features affect clinical management and antagonism.
5. Highlights implications for prevention, toxicology, and guidelines for dealing with fentanyl-class opioids.

The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies

1. Describes the development of the illicit fentanyl crisis with a sharp increase in deaths since ~2013 and geographical patterns.
2. Fentanyl is approximately 30–50 times more potent than heroin and is increasingly detected as an adulterant in stimulants and other drugs.
3. Pathophysiology centers on rapid respiratory depression with cardiovascular and neurological complications.
4. Acute management relies on naloxone, though effectiveness is inconsistent, highlighting a need for optimized strategies.
5. Future therapeutic options include vaccines and monoclonal antibodies, alongside expanded harm reduction measures.

A holistic review of fentanyl use and its impact on public health

1. Provides a holistic overview including synthesis, pharmacology, clinical use, epidemiology, and global distribution of fentanyl.
2. Documents the continuing rise of illicitly manufactured fentanyl and increasing overdose mortality.
3. Links fentanyl use with alterations in the gut microbiome (dysbiosis) and potential effects on reinforcement and reward pathways.
4. Describes user motivations and patterns (intentional use versus avoidance; socioeconomic and polysubstance factors).
5. Stresses the importance of OAT, naloxone strategies, and harm reduction, as well as the development of stronger and longer-lasting antagonists.

Pharmacokinetics of Novel Synthetic Opioids: Clinical Implications for Overdose and Treatment

1. This review summarizes the pharmacokinetic properties of novel synthetic opioids, describing absorption, distribution, metabolism, and excretion.
2. The authors emphasize that many synthetic opioids have very high potency and prolonged half-lives, which increases the risk of drug accumulation and overdose.
3. A large proportion of these opioids are metabolized by cytochrome P450 enzymes, raising concerns for drug–drug interactions with medications commonly used in clinical practice.
4. The variability in pharmacokinetics among different synthetic opioids complicates overdose management and may require higher or repeated naloxone dosing.
5. The article calls for more systematic research to inform treatment guidelines and optimize harm reduction strategies in the context of synthetic opioid exposure.

Implementation of Overdose Education and Naloxone Distribution in Community Settings

1. This systematic review analyzed the implementation of overdose education and naloxone distribution programs across a wide range of community settings.
2. The review found consistent evidence that these programs improve knowledge about overdose, increase naloxone availability, and enhance the ability of laypeople to respond effectively to overdoses.
3. Common barriers to implementation included stigma toward people who use drugs, costs of program delivery, lack of training, and fragmented or inconsistent policy support.
4. Successful implementation was supported by strong community partnerships, enabling legislation and legal protections, and integration with broader harm reduction initiatives.
5. The review concludes that overdose education and naloxone distribution are effective strategies and should be expanded through supportive policy and sustainable funding.

Take-Home Naloxone Programs: A Global Review

1. This global review provides a comprehensive overview of take-home naloxone (THN) programs, tracing their history, coverage, and documented outcomes.
2. The review documents that THN programs have now been adopted in more than 20 countries and have contributed to reductions in opioid overdose mortality.
3. Major challenges to the expansion of THN include inadequate coverage, variability in training quality, and persistent legal and regulatory barriers in some settings.
4. Evidence shows that active community engagement and linking THN to other harm reduction services are critical for program effectiveness.
5. The authors argue that global expansion of THN should be prioritized, with a focus on equitable access and systematic evaluation of outcomes.

Naloxone

1. This StatPearls entry provides an overview of naloxone as an opioid antagonist used for over half a century in the reversal of opioid overdoses and related emergencies.
2. The pharmacology of naloxone is described, including its role as a competitive antagonist at the µ-opioid receptor, rapid onset of action, and relatively short half-life.
3. Clinical use encompasses multiple routes of administration such as intravenous, intramuscular, subcutaneous, and intranasal delivery, each with distinct onset and duration profiles.
4. Potential adverse effects include acute withdrawal symptoms, agitation, and, in rare cases, cardiovascular complications, particularly in opioid-dependent individuals.
5. The entry emphasizes the importance of interprofessional collaboration, patient and community education, and broad accessibility of naloxone as essential components for reducing overdose deaths.

Barriers and Facilitators to Naloxone Access in Community Pharmacies: A Qualitative Study

1. This qualitative study explores the perspectives of pharmacists regarding the barriers and facilitators to naloxone access in community pharmacies.
2. Pharmacists identified significant barriers, including pervasive stigma toward opioid use, inadequate training, limited consultation time, and inconsistent reimbursement mechanisms.
3. Facilitators included the presence of supportive policies, professional guidelines, and demonstrated community demand for naloxone access.
4. The study highlights the proactive role that pharmacists can play in naloxone distribution, particularly in expanding access and normalizing its use as a public health measure.
5. Recommendations include strengthening pharmacist training, establishing clearer reimbursement mechanisms, and implementing anti-stigma interventions to improve equitable community access to naloxone.

Harm Reduction: A Concept Analysis

1. This concept analysis used Rodgers’ evolutionary method to clarify harm reduction’s attributes and context.
2. Five defining attributes were identified: safety, supplies, education, partnerships, and policy.
3. Applications discussed include syringe service programs, supervised consumption sites, medication-assisted treatments, and naloxone distribution.
4. Antecedents include the presence of harm and substance use crises; consequences include reduced morbidity and mortality.
5. The paper highlights the role of nurses and the need for concept clarity to guide practice and policy.

Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs

1. This review discusses harm reduction services (e.g., syringe service programs, supervised consumption) to prevent and treat infectious diseases in people who use drugs.
2. Syringe service programs are described as essential for reducing HIV, HCV, and other infections among PWID.
3. The article emphasizes integration of harm reduction into broader preventive and clinical care frameworks.
4. Structural barriers including stigma, criminalization, and inequitable access limit service reach.
5. The authors advocate for multidisciplinary, justice-oriented approaches to improve health outcomes for PWID.

Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings

1. This review explores how harm reduction strategies can be integrated into outpatient opioid use disorder (OUD) treatment.
2. It emphasizes aligning harm reduction with chronic care models and patient-centered approaches.
3. Specific interventions include naloxone distribution, syringe access, and safer use education within OUD care.
4. Barriers identified include stigma, regulatory restrictions, and insufficient provider training.
5. The authors call for systemic changes to embed harm reduction in OUD treatment and improve engagement and outcomes.

Drug checking services for people who use drugs: a systematic review

1. This systematic review (1990–2019; 90 studies) synthesizes evidence on drug checking services (DCS) across behavior change, market monitoring, and service models.
2. DCS commonly detected unexpected contents, new psychoactive substances, and drugs of concern (e.g., fentanyl), enabling public health alerts and surveillance.
3. Behavioral intentions and actions (e.g., not using, using less, disposing) were more likely to change when results were unexpected or indicated drugs of concern.
4. Evidence quality was generally low and heterogeneous, with most studies from European party settings and fewer among structurally vulnerable populations.
5. Further rigorous research is needed to link DCS-induced behavior change to health outcomes and to evaluate models beyond party settings.

Beyond the Buzzword: A Concept Analysis of Harm Reduction

1. Using Rodgers' evolutionary concept analysis, the authors identify seven defining attributes of harm reduction (e.g., focus on harms, participation of people who use drugs, human rights, pragmatism).
2. Harm reduction is framed as a public health approach that is adaptable and innovative, extending beyond simple use reduction or abstinence-only strategies.
3. The analysis distinguishes harm reduction from related terms (e.g., harm minimization) and clarifies antecedents, consequences, and related concepts.
4. Implications emphasize avoiding vague buzzword usage by grounding practice in clear principles and meaningful involvement of people who use drugs.
5. The paper argues for policy and practice alignment with harm reduction values across healthcare, community, and government settings.

A systematic review of stigma interventions for providers who treat patients with substance use disorders

1. This systematic review identified six types of provider-directed stigma interventions (e.g., online education, in‚Äëperson education, contact with individuals in recovery, communication training).
2. Across heterogeneous samples (N≈1324), educational and contact-based approaches generally improved provider attitudes toward patients with SUDs.
3. Interventions including direct contact with people in recovery showed more durable attitudinal change than education alone.
4. Methodological quality was limited, with heterogeneity and scarce measurement of behavioral or clinical outcomes; implementation metrics (e.g., sustainability) were rarely reported.
5. The authors recommend theory-informed, practical, and cost‚Äëeffective interventions that incorporate consumer contact and assess long‚Äëterm impact and implementation outcomes.

What Predicts Beneficial Outcomes in Psychedelic Use? A Quantitative Content Analysis of Psychedelic Health Outcomes

1. This study compared metaphysical belief theory and predictive self-binding theory in explaining psychedelic benefits.
2. A content analysis of 240 unsolicited reports from Erowid.org was conducted.
3. Psychological insight, not metaphysical beliefs, predicted beneficial outcomes.
4. Ego dissolution and therapeutic intent effects were mediated by psychological insight.
5. Findings support predictive self-binding theory over metaphysical belief theory.

Association of Recreational Cannabis Legalization with Frequency of Using Cannabis for Sleep

1. This study examined the link between recreational cannabis legalization (RCL) and cannabis use for sleep.
2. Data from 3,141 adult twins were analyzed using linear regression models.
3. RCL was associated with increased frequency of cannabis use for sleep.
4. No association was found for alcohol or sleep medication use.
5. The findings suggest RCL may promote cannabis use for sleep, warranting further research.

Negotiating the divide: Science, politics, and institutional boundaries in Swiss cannabis regulation

1. This qualitative study explores 'boundary work' in Swiss cannabis regulation.
2. Eighteen stakeholder interviews examined distinctions between medical and non-medical cannabis.
3. Conceptual boundary work legitimizes medical cannabis as scientific and frames non-medical as social/political.
4. Structural mechanisms, like insurance reimbursement, reinforce these boundaries.
5. The study warns that some regulatory elements risk blurring intended distinctions.

Advancing ketamine in the treatment hierarchy for refractory depression

1. Ketamine shows high efficacy and tolerability for refractory depression.
2. Evidence suggests earlier use may improve outcomes compared to current augmentation strategies.
3. Side effects are generally transient and less severe than with many alternatives.
4. Economic and logistical barriers limit broader adoption.
5. The authors call for trials comparing early ketamine use with standard care.

A clarion call to the addiction science community: It’s time to resist the anti-scientific policies of the US Trump administration

1. This editorial condemns recent US government actions undermining addiction science.
2. It cites censorship of gender-related terminology in CDC publications.
3. It warns of funding cuts, halted clinical trials, and threats to research infrastructure.
4. The authors urge coordinated action by journals, societies, and scientists.
5. Protecting scientific integrity is framed as essential for public health.

Naloxone dosing: An evolving unregulated drug landscape, care setting considerations, and the need for research

1. Reviews complexities in naloxone dosing amid potent synthetic opioids.
2. Advocates titration to effect in acute settings but notes limits in community settings.
3. Highlights pharmacokinetic/pharmacodynamic challenges with fentanyl and analogs.
4. Discusses administration routes: IV preferred in hospital, IM in community.
5. Calls for clinical trials in synthetic opioid and polysubstance overdose contexts.

A proportionality approach to the ethics of drug policy

1. Proposes applying proportionality principle to assess ethical drug policy.
2. Integrates consequentialist and deontological reasoning in proportionality judgments.
3. Argues drug policy is inherently value-laden and not purely evidence-based.
4. Provides analytical framework to reveal implicit normative premises.
5. Applies the framework to demand, supply, and harm reduction policies.

Therapeutic Potential of Psychedelics for Treating Anosmia: An Investigation of Online Accounts

1. Analyzed 125 online posts on psychedelics and olfactory dysfunction (OD).
2. 86.4% reported improved smell after psychedelic use.
3. Half noticed improvement during the trip, ~39% had effects lasting ≥1 day.
4. No dose-response relationship found for LSD or psilocybin.
5. Suggests further research to assess clinical potential and mechanisms.

Setting the Stage for the Inner Journey: Unraveling the Interplay of Contextual Factors and the Intensity of Psychedelic-Induced Ego Dissolution

1. Surveyed 862 psychedelic users on motivations, environments, and ego dissolution intensity.
2. Spiritual/self-healing motives linked to stronger ego dissolution.
3. Curiosity motives linked to weaker ego dissolution.
4. Social/physical environment not significantly associated.
5. Highlights role of 'set' over 'setting' in naturalistic contexts.

Sex Differences in Religious Beliefs Before and After an Entity Encounter During an Ayahuasca Experience

1. Surveyed 415 ayahuasca users reporting entity encounters.
2. Men were more likely to be atheists pre-encounter, but differences disappeared after.
3. Both sexes showed increased religious beliefs post-encounter.
4. Men's change toward religiosity was statistically significant; women's was not.
5. Suggests entity encounters can shift religious beliefs, with sex-specific patterns.

Personal Psychedelic Experience as a Training Qualification for Facilitators: A Thematic Analysis of Qualitative Interviews with Psilocybin Experts

1. Interviewed 36 psilocybin facilitators on personal psychedelic experience as a qualification.
2. Most supported it, citing benefits for empathy, understanding, and wellbeing.
3. One participant questioned necessity of personal use.
4. Legal frameworks in Oregon and Colorado do not require it.
5. Suggests research on links between facilitator experience and client outcomes.

Religion, Psychedelics, Risky Behavior, and Violence

1. Analyzed NSDUH data (2015-2019) on psychedelics, religion, and violence.
2. Lifetime classic psychedelic use and religious salience independently reduced violence.
3. High religious salience moderated risky behavior–violence link.
4. Psychedelic use plus high religious salience had strongest protective effect.
5. Suggests cultural context shapes behavioral outcomes of psychedelic use.

Trainees Unprepared for Advances in Psychedelic Medicine: A Survey Study

1. Surveyed 221 medical and allied health trainees on psychedelic medicine preparedness.
2. Most learned from social media/word-of-mouth, not formal education.
3. Knowledge levels generally low; structured training rare.
4. Institutional programming predicted greater literacy.
5. Recommends integrating psychedelics into curricula.

Psychedelic Microdosing among Young Adults from Southern California

1. Surveyed 2,396 young adults (18-22) on awareness and practice of microdosing.
2. 12% heard of microdosing; 3% had tried it.
3. Psilocybin most common, followed by LSD.
4. Some used doses higher than typical microdose.
5. Identified demographic and behavioral correlates of microdosing.

Healthcare provider stigma toward patients with substance use disorders

1. National probability survey (n=1240) of PCPs, emergency physicians, and dentists measured stigma across SUDs versus diabetes, depression, and HIV.
2. Stigma was highest for stimulant use disorders and higher for OUD than AUD; lowest for diabetes.
3. Emergency physicians showed greater stigma than primary care, who in turn exceeded dentists.
4. Lower stigma correlated with providing referrals, offering MOUD, and having SUD consultation available.
5. Findings suggest reducing provider stigma could improve SUD screening, referral, and treatment uptake.

Transitions to legal cannabis markets: Legal market capture of cannabis expenditures in Canada following federal cannabis legalization

1. Demand‑side estimates combining CCHS prevalence and ICPS expenditure data put Canada’s 2022 cannabis market at CAD $6.72B.
2. An estimated 78% of expenditures came from legal sources, closely matching government retail sales data (within ~2 percentage points).
3. Product shares of legal spending: dried flower 55%, concentrates 12%, oral liquids 11%, vaping liquids 10%, edibles 8% (plus 2% plants/seeds).
4. Self‑reported legal sourcing aligned with objective sales, indicating substantial displacement of illicit markets five years post‑legalization.
5. Results support legalization’s goal of transitioning consumers to quality‑controlled legal supply.

Psychedelic Experiences Increase Mind Perception but do not Change Atheist-Believer Status: A Prospective Longitudinal Study

1. Prospective study (N=657) of planned psilocybin use outside labs assessed mind perception, metaphysical beliefs, and atheist‑believer status pre/post.
2. Mind perception increased across living and non‑living targets (e.g., plants, rocks) after the experience.
3. Little to no change was observed in metaphysical beliefs (e.g., dualism) or atheist‑believer status.
4. Findings contrast with cross‑sectional reports of large belief shifts following psychedelics.
5. Results highlight mind perception/mentalization as more malleable than core metaphysical commitments.

Characteristics of Overdose Deaths Related to Illicitly Manufactured Fentanyl – Arizona, July 2019 – June 2020

1. Analysis of AZ‑SUDORS data (2019–2020) categorized 2,029 overdose decedents by opioid involvement, with 57.9% IMF‑positive.
2. IMF decedents were younger (mean 35), more urban (78.2%), and more often racial/ethnic minorities (48.6%) than other groups.
3. IMF cases were less likely to be methamphetamine‑positive (24.9%) than heroin (63.7%) or pharmaceutical opioid groups (34.0%).
4. Cannabis co‑positivity was higher among IMF decedents (31.3%) than in the other groups.
5. Data suggest tailoring prevention and harm‑reduction to distinct psychosocial profiles associated with IMF exposure.

Psychotropic Taxonomies: Constructing a Therapeutic Framework for Psychiatry

1. Reviews historical and current taxonomies, arguing disease‑based labels (e.g., ‘antidepressant’) poorly reflect transdiagnostic usage and biology.
2. Frames a spectrum from high‑level disease‑based to target‑based molecular classification and their clinical/developmental implications.
3. Advocates intermediate, data‑driven classes grounded in neurobiological and psychopathological markers.
4. Highlights how classifications shape not only practice but also models of disease and drug development.
5. Proposes a 21st‑century taxonomy integrating multilevel mechanisms to guide treatment selection and innovation.

Did the United States smokeless tobacco industry use cigarette industry strategies to sponsor and manipulate research?

1. Internal documents (1970s–1990s) indicate SLT industry adopted cigarette‑industry strategies to shape research agendas.
2. Guided by legal counsel, the Smokeless Tobacco Research Council emphasized projects supporting industry positions and criticized adverse findings.
3. Portfolio analysis showed heavy funding for nicotine‑related topics (78/189) and underfunding of epidemiology (n=3).
4. Some projects on constituents (e.g., N‑nitrosonornicotine) could implicate carcinogenesis despite industry ties.
5. Overall, governance and grantmaking structures likely favored industry interests over independent scientific discovery.

Rare but relevant: Ketamine‐induced cystitis – an in‐depth review for addiction medicine

1. Summarizes pathophysiology implicating urothelial toxicity, inflammation, and nerve hyperplasia driven by ketamine/norketamine metabolites.
2. Urinary biomarkers (e.g., IL‑6, iNOS) support an inflammatory mechanism in ‘ketamine bladder’.
3. Presents a staged clinical framework, with early stages potentially reversible upon cessation.
4. Management emphasizes abstinence, multimodal symptom control, and urology‑addiction collaboration, aligning with BAUS consensus.
5. Highlights growing clinical relevance amid recreational/off‑label ketamine use.

The language of alcohol: Similarities and differences in how drinkers and policymakers frame alcohol consumption

1. Corpus analysis compared drinkers’ narratives (TDC) with English policy texts (TPC) using Wmatrix semantic domains.
2. Both corpora overused domains like Cause‑Effect, Disease, Drinks/Alcohol, Excessive drinking, and Knowledge relative to general usage.
3. Policy texts foregrounded long‑term harms (e.g., liver disease), while drinkers emphasized short‑term effects (e.g., hangovers).
4. Drinkers’ corpus featured more ‘Emotional actions’; policy corpus emphasized ‘Social actions/states/processes’ and behavior change.
5. Authors recommend closer dialogue with drinkers to improve policy resonance and effectiveness.

Neural Signatures of Cognitive Control Predict Future Adolescent Substance Use Onset and Frequency

1. Seven‑year longitudinal fMRI study (n=91) found stronger dACC–dlPFC connectivity predicted delayed substance use onset.
2. A marked decline in dACC–dlPFC connectivity was observed about one year before initiation.
3. Lower dACC–SMA and higher anterior insula connectivity with dmPFC/angular gyrus predicted greater future use frequency.
4. Effects held after adjusting for demographics and socioeconomic factors.
5. Implications include targeting top‑down control and interoceptive processes in early prevention.

Psilocybin in alcohol use disorder and comorbid depressive symptoms: Results from a feasibility randomized clinical trial

1) Double-blind, 2:1 pilot RCT (25 mg vs 1 mg) in recently detoxified AUD with depressive symptoms.
2) Feasibility met; blinding imperfect (patients 93%, investigators 87% guessed correctly).
3) At 12 weeks: higher abstinence (55% vs 11%) and fewer drinking days/craving in 25 mg group.
4) Relapse HR 0.52 favoring 25 mg; adverse events comparable; one MI unrelated to treatment.
5) Suggests psilocybin-assisted psychotherapy feasible/safe with preliminary efficacy signals.

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study

1) Phase I double-blind, placebo-controlled; weekly sublingual 5-MeO-DMT microdoses (6–12 mg) x4.
2) Well tolerated; no serious drug-related AEs or organ toxicity; mild transient nausea/headache.
3) Rapid absorption (median Tmax ~20 min); no accumulation across doses.
4) Neurophysiology: dose-dependent brain modulation without full psychedelic effects.
5) Supports feasibility of repeated sub-perceptual dosing for future clinical trials.

Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study

1) Online survey of 346 LGBTQIA+ participants on naturalistic psychedelic use and identity/mental health.
2) Reported reductions in traumatic stress, depression, and anxiety; increased psychological flexibility.
3) 77% endorsed therapeutic potential for gender dysphoria; 65% reported shifts in gender identity attitudes.
4) Greater acute effect intensity associated with higher self-acceptance and identity exploration (canonical Rc≈0.49).
5) Suggests benefits for marginalized groups; underscores need for prospective/controlled studies.

Response to “Do We Need On-Site Drug Analysis Within Supervised Injecting Facilities?”

1) Argues onsite drug analysis complements supervision by preventing avoidable adverse events.
2) Notes contaminated supply and risks persisting beyond supervised settings; testing informs harm-reduction advice.
3) Counters claim that MSIC safety record precludes added benefit; highlights morbidity from hypoxia.
4) Post-event toxicology often unhelpful; onsite testing better supports proactive risk management.
5) Advocates integrating testing within supervised injecting facilities as standard practice.

Religious Social Integration, Psychedelics, and Psychological Distress

1) NSDUH 2008–2019 data (n≈458,372) examined links between lifetime classic psychedelic use, religiosity, and distress.
2) Both religious involvement and psychedelic use associated with lower psychological distress (K6).
3) High religious salience generally reduces distress, but effect attenuated among psychedelic users.
4) Three-way interaction: high salience + high attendance + psychedelic use linked to lowest distress.
5) Highlights sociocultural moderators shaping psychedelic-health relationships.

Lisdexamfetamine in the treatment of methamphetamine dependence: A randomised, placebo-controlled trial

1) Multisite RCT (n=164) testing 12-week lisdexamfetamine 250 mg vs placebo in methamphetamine dependence.
2) Primary endpoint (days used at week 13) showed only weak benefit.
3) Over full 12-week maintenance, lisdexamfetamine group had fewer total use-days (Δ≈8.8 days; p=0.005).
4) Better self-reported effectiveness and satisfaction; AEs included nausea; few serious AEs.
5) Suggests reduction in use during treatment, uncertain durability post-treatment.

How to improve psychiatric nosography in the XXI century: a phenomenologist’s viewpoint

1) Argues DSM editions reflect sociocultural forces and stakeholder interests more than patients’ lived experience.
2) Rapid sociocultural change yields fragmented, episodic suffering that escapes symptom-based nosography.
3) Advocates a paradigm shift: from syndromic aggregation to grasping clinical 'fragments' and 'existential knots.'
4) Emphasizes the 'clinical factor' over impact factor; align nosography with frontline therapeutic needs.
5) Proposes provisional catalog of existential knots as navigational aids in clinical practice.

Getting 'The whole picture': A review of international research on the outcomes of regulated cannabis supply

1. Reviewed outcomes of cannabis regulation in five jurisdictions using systematic literature review.
2. Found consistent decreases in cannabis-related arrests across all regions.
3. Observed increase in adult cannabis use, but not among adolescents.
4. U.S. states showed increased health care utilization and some negative health outcomes.
5. Study highlights trade-offs and calls for nuanced cannabis policy research.

Psychedelic Use and Behavioral Addictions

1. Surveyed 1107 individuals for behavioral addiction symptoms and psychedelic use.
2. Found psychedelic use associated with higher well-being and lower addiction scores.
3. Behavioral addictions clustered as one factor in PCA analysis.
4. Stimulant, alcohol, and nicotine use linked to increased behavioral addiction.
5. Psychedelics predicted lower behavioral addiction scores uniquely.

Exploring Motivations, Experiences, and Consequences of Psychedelic Use in Aotearoa New Zealand

1. Surveyed 997 individuals about psychedelic use in New Zealand.
2. Typical experiences closely resembled best experiences; worst experiences were emotionally distinct.
3. Growth-oriented motivations predicted positive psychological outcomes.
4. Frequency and type of use influenced perceived benefits.
5. Emphasizes need for reform in drug education and harm reduction policies.

The Effect of Modafinil Treatment on Cravings in Methamphetamine Use Disorder

1. Compared craving reduction in 100 methamphetamine users with and without modafinil.
2. Modafinil group showed greater craving reduction in first week.
3. No significant difference after two weeks.
4. Craving scores at baseline were higher in modafinil group.
5. Modafinil may be effective in early treatment phase for high-craving patients.

Can ‘justified disapproval’ be separated from addiction stigma? An empirical focus is required

1. Examines whether 'justified disapproval' can be conceptually separated from addiction stigma.
2. Highlights lack of empirical support for normative disapproval as a constructive strategy.
3. Reviews behavioral science and social norm theories in addiction context.
4. Argues disapproval strategies risk reinforcing harmful stigma.
5. Recommends alternative approaches focusing on structural and cultural drivers of addiction.

Use of psychedelic treatments in psychiatric clinical practice: an EPA policy paper

1. Outlines the current evidence and regulatory developments in psychedelic therapy.
2. Highlights therapeutic potential and risks of substances like psilocybin and LSD.
3. Emphasizes importance of ethical, psychosocial and professional frameworks.
4. Identifies methodological and clinical implementation challenges.
5. Recommends balanced policy development based on scientific evidence.

Sleep-administered ketamine/psychedelics: A streamlined strategy to address two challenges in research on ketamine and psychedelics

1. Proposes sleep administration to improve blinding in ketamine/psychedelic trials.
2. Suggests dissociative effects may compromise double-blind study designs.
3. Argues sleep administration could reduce expectancy bias and placebo effects.
4. Considers implications for understanding dissociation's role in antidepressant action.
5. Suggests practical, scalable alternatives to general anesthesia masking.

The efficacy, mechanisms and implementation of physical activity as an adjunctive treatment in mental disorders: a meta-review of outcomes, neurobiology and key determinants

1. Meta-review of 256 RCTs on physical activity in mental disorders.
2. Found large effects for depression, ADHD, and schizophrenia symptom reduction.
3. Described neurobiological pathways involving BDNF, inflammation, neurotransmitters.
4. No meta-analytic evidence yet for psychosocial mechanisms.
5. Identified six implementation strategies based on 432 studies.

Understanding the Experience of Ketamine-Assisted Therapy and the Importance of Context

1. This qualitative study explores patients' experiences with ketamine-assisted therapy (KAT) for treatment-resistant depression.
2. Thematic analysis identified key therapeutic factors: openness, therapeutic alliance, safety, and set/setting.
3. Contextual elements like music and the therapist’s own experience contributed to perceived therapeutic benefit.
4. Vulnerabilities were also reported, especially related to trauma surfacing during sessions.
5. Findings underscore the importance of contextual and relational aspects in KAT's effectiveness.

Cannabis User Perceptions: General and Oral Health Benefits and Harms of Vaping Versus Smoking

1. The study surveyed cannabis users on perceived general and oral health effects of vaping vs. smoking.
2. Most users saw vaping as less harmful, especially regarding pain management and mood enhancement.
3. Women and younger users favored vaping for emotional well-being and stress relief.
4. Concerns remained about habit formation and possible cardiovascular and dental effects.
5. Results suggest the need for interprofessional education on cannabis-related health impacts.

Exploring the Suitability of Cannabis Use with Next-Day Responsibilities: A Behavioral-Economic and Qualitative Study

1. This study examined how next-day responsibilities impact cannabis consumption in regular users.
2. Cannabis demand decreased significantly in responsibility conditions like job interviews or childcare.
3. Suitability perceptions influenced demand: higher perceived appropriateness led to higher consumption.
4. Qualitative data highlighted reasons for perceived compatibility or incompatibility of cannabis use.
5. Results support context-specific cannabis use research for public health and policy.

“Stoned on the Road”: A Systematic Review of Cannabis-Impaired Driving Educational Initiatives Targeting Young Drivers in Canada

1. This systematic review examined Canadian educational initiatives addressing youth cannabis-impaired driving (DUIC).
2. Fifteen programs were identified, including workshops, apps, and digital campaigns at national and regional levels.
3. Awareness was improved, but long-term behavioral change evidence was limited.
4. Financial sustainability and digital platform maintenance were key challenges.
5. The authors call for future focus on impact evaluation and sustainable delivery.

Vermont Primary Care Provider Perspectives on Psychedelics — A Cross-Sectional Study

1. This survey explored Vermont primary care providers’ attitudes toward therapeutic psychedelics.
2. Most were familiar with psychedelics and cautiously optimistic about their potential benefits.
3. Key concerns included youth risk, psychosis, and traffic safety.
4. Only a minority were fully informed about the legal status of key substances.
5. A large majority expressed interest in further education on the topic.

Tripping into Treatment: Comparing Initial and Current Motivations for Psychedelic Use

1. This study surveyed psychedelic users about their initial and current motivations for use.
2. Initial use was mostly recreational or exploratory, while current use was more therapeutic.
3. Motivations shifted toward managing mental health, trauma, and personal growth.
4. Retrospective design limits causality, but highlights motivational evolution over time.
5. Results inform both harm reduction and therapeutic intervention strategies.

Oregon’s Emerging Psilocybin Services Workforce: A Survey of the First Legal Psilocybin Facilitators and Their Training Programs

1. This study surveyed early licensed psilocybin facilitators and training programs in Oregon.
2. The training programs were diverse and often financially burdensome for participants.
3. Facilitators specialized in areas like trauma, consciousness exploration, and mental health.
4. Diversity scholarships were common, but ongoing training needs remain high.
5. Findings guide future workforce development and policy in psychedelic services.

Psychedelic Drug Microdosing Practices: A Qualitative Online Exploration

1. This qualitative study analyzed Reddit posts from r/microdosing to understand user motivations and outcomes.
2. Commonly cited benefits included mood enhancement, increased creativity, and improved focus.
3. Negative effects included fatigue, anxiety, and increased emotional sensitivity.
4. Most users reported using psilocybin or LSD and loosely followed Fadiman’s protocol.
5. Authors highlight the need for controlled research due to wide variation in practices and experiences.

Exploring Public Sentiments of Psychedelics Versus Other Substances: A Reddit-Based Natural Language Processing Study

1. The study used NLP to analyze 10,000 Reddit posts comparing perceptions of psychedelics, alcohol, tobacco, cannabis, and opioids.
2. Psychedelics received more positive sentiment, especially related to therapeutic and spiritual effects.
3. Opioids and alcohol were associated with negative outcomes and stigma.
4. Cannabis received mixed evaluations, balancing benefits and concerns.
5. The findings suggest increased online support for psychedelics compared to other substances.

Patients’ Attitudes Toward Hallucinogenic and Non-Hallucinogenic Psilocybin for Mental Health Treatment

1. Survey of psychiatric patients on preferences for hallucinogenic vs non-hallucinogenic psilocybin.
2. Patients with depression preferred hallucinogenic versions; PTSD and BPD patients preferred non-hallucinogenic forms.
3. Individuals with SUD showed openness to both types.
4. The study indicates stigma is not a main barrier.
5. Findings suggest that non-hallucinogenic options may expand accessibility.

The impacts of e-cigarette flavours: An overview of systematic reviews

1. This overview synthesizes 14 systematic reviews on flavored e-cigarettes and public health.
2. Flavored e-cigarettes increase appeal, particularly among youth.
3. Some evidence suggests flavors help adult smokers quit, but findings are limited.
4. Flavor bans could reduce youth uptake but may hinder harm reduction.
5. Balanced regulation is required to protect youth while supporting smoking cessation.

Psychosis associated with cannabis withdrawal: systematic review and case series

1. This systematic review and case series identified 112 cases of psychosis following abrupt cannabis withdrawal.
2. Most individuals were heavy daily users who ceased use suddenly.
3. Cannabis withdrawal symptoms preceded psychosis, including irritability, insomnia, and appetite loss.
4. Relapse was more common in those who resumed cannabis use post-episode.
5. Cannabis withdrawal can be a trigger for both first-episode and recurrent psychosis.

Relative efficiency of psychiatric clinics in treating cases without coercion and achieving symptom reduction

1. The study used Data Envelopment Analysis to compare 22 Swiss psychiatric clinics on coercion-free treatment efficiency.
2. Clinics could reduce coercive measures by 9% and improve symptom reduction by up to 34% with unchanged staffing.
3. Highest management-driven efficiency gains were possible in reducing movement restrictions.
4. Efficiency scores were unrelated to clinic size, highlighting the role of management practices over resources.
5. The study suggests structural reforms and staff training as cost-effective strategies to improve outcomes.

What can we learn from low-THC cannabis growers in Europe? A comparative transnational study of small-scale cannabis growers from Italy and Switzerland

1. This study compares low-THC (LT) and high-THC (HT) cannabis growers in Italy and Switzerland based on survey data.
2. LT growers are older, grow more for medical and legal reasons, and report fewer problematic use patterns.
3. HT growers cultivate more extensively and effectively meet personal consumption needs.
4. LT growers more often produce by-products like oils and extracts and face more legal contact.
5. The LT market appears to attract previous HT growers transitioning to legal cultivation, not new users.

Magic of the Mushrooms: Effects of Psilocybin Decriminalization

1. This study analyzes U.S. search trends and finds increased interest in psilocybin after decriminalization in cities and states.
2. Psilocybin decriminalization coincides with decreased public interest in LSD and MDMA, suggesting substitution effects.
3. The authors argue psilocybin is safer than other psychedelics and could improve public health outcomes.
4. The reforms are inspired by marijuana legalization trends and could expand to other states.
5. The study highlights the value of internet data as early indicators of drug policy impact.

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

1. This review describes the Swiss program for limited medical use of psychedelics (MDMA, LSD, psilocybin) under special authorization.
2. Since 2014, over 700 patients have been treated by about 100 physicians, mostly for conditions like PTSD or end-of-life anxiety.
3. The program requires absence of alternative treatments and evidence of incurability.
4. Comparison with similar programs in Canada and Australia highlights differences in regulation, training, and costs.
5. The article discusses legal, clinical, and organizational structures relevant to stakeholders planning similar initiatives.

Psychosis associated with cannabis withdrawal: Systematic review and case series

1. This study found 44 published cases and 68 health record cases where psychosis followed cannabis withdrawal.
2. Most cases involved daily cannabis users who stopped abruptly.
3. Relapse was significantly more likely in those who resumed cannabis use.
4. Cannabis withdrawal symptoms often preceded psychosis onset by a few days.
5. Authors highlight the importance of recognizing withdrawal as a potential psychosis trigger.

Extended-Release Injectable Buprenorphine for the Treatment of Opioid Use Disorder Among Individuals at High Risk of Overdose: The FASTER-BUP Study.

1. This 24-week observational study assessed XR-buprenorphine (XR-BUP) among high-risk opioid users in Vancouver.
2. Only 32% completed all six monthly injections; the median number was two.
3. Participants continued to use illicit opioids with 28.5% opioid-free visits.
4. No serious adverse events were reported; injection site reactions were mild.
5. Despite tolerability, treatment retention was low, questioning the model's utility.

Cannabis and driving: A repeat cross-sectional analysis of driving after cannabis use pre- vs. post-legalization of recreational cannabis in Canada

1. National surveys (2018–2023) assessed driving after cannabis use in Canada before and after legalization.
2. Post-legalization, prevalence of driving after cannabis use increased overall but remained stable among users.
3. In 2022 and 2023, significantly more people reported driving post-consumption than in 2018.
4. No change in prevalence of being a passenger with a driver who used cannabis.
5. Findings highlight the need for targeted prevention strategies despite general legalization.

Obsessive-compulsive disorder with hoarding behavior: unravelling key differences

1. Compared 663 OCD patients with hoarding to 1247 without in the Genomic Psychiatry Cohort.
2. OCD+hoarding individuals had lower education, were more often single, and lived alone.
3. They had more severe OCD symptoms and poorer insight.
4. Comorbidities like depression, PTSD, schizophrenia, and ADHD were significantly more frequent.
5. Findings support the conceptualization of hoarding as a distinct subtype needing specific attention.

Recent increases in crack injection and associated risk factors among people who inject psychoactive drugs in England and Wales

1. Crack injection among PWID in England and Wales rose from 34% (2011) to 57% (2020/21).
2. Co-injection with heroin and behaviors like groin injecting and syringe sharing were common.
3. Crack injectors had higher overdose and hepatitis C rates.
4. Risk behaviors suggest a need for adapted harm reduction services.
5. Structural responses are needed to reduce BBV and SSTI risks.

Trends and correlates of naloxone possession and use among people who inject drugs in Seattle, Washington

1. This study assessed trends in naloxone possession and use among PWID in Seattle (2012–2019).
2. Naloxone possession increased 2.8x in SSP and NHBS populations over the period.
3. Use of naloxone to reverse overdoses also increased.
4. Increased access likely reflects effective policy and programmatic interventions.
5. Despite progress, disparities remain and further equity-focused efforts are needed.

A Psilocybin Experience Gone Wrong: The Importance of Psychedelic Assisted Psychotherapy

1. Case study of a negative psilocybin experience without proper therapeutic support.
2. Patient required inpatient psychiatric care due to psychological destabilization.
3. Highlights the need for structured psychedelic-assisted psychotherapy (PAP).
4. Supports the argument for experiential training among PAP prescribers.
5. Illustrates risks of unregulated or unsupported psychedelic use.

Patterns of past month cannabis consumption and cannabis use disorder – Insights from a nationally representative survey

1. Survey of 1,719 US adults reporting past-month cannabis use.
2. 26% of medical users and 21% of recreational users met CUD criteria.
3. CUD rates increased with frequency of use, highest among daily users.
4. Young adults and men had highest CUD prevalence.
5. Results support more granular monitoring of use patterns in public health.